Omniab, Inc. company information, Employees & Contact Information

OmniAb to Report Third Quarter 2025 Financial Results on November 4 Business Wire

OmniAb to Participate in Three Investor Conferences in November FinancialContent

OmniAb to Participate in Three Investor Conferences in November Business Wire

OmniAb, Inc. (OABI) Reports Q2 Loss, Lags Revenue Estimates Yahoo Finance

OmniAb: Too Much Risk, Not Enough Reward (NASDAQ:OABI) Seeking Alpha

OmniAb Announces $30 Million Private Placement Business Wire

Latham & Watkins Advises OmniAb on US$30 Million Private Placement Latham & Watkins LLP

OmniAb (OABI) Price Target Increased by 10.30% to 8.84 Nasdaq

Veraxa and OmniAb to develop bispecific ADC tumour programme Pharmaceutical Technology

OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today’s Research & Technology Virtual Event The AI Journal

OmniAb Q2 2025 slides: Partner growth accelerates despite revenue decline Investing.com

OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights Business Wire

Contact - The Lethbridge Herald - News and Sports from around Lethbridge FinancialContent

Insider Stock Buying Reaches US$1.48m On OmniAb Yahoo Finance

OmniAb Second Quarter 2025 Earnings: Revenues Disappoint Yahoo Finance

Companies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In Growth Yahoo Finance

Is OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030? Yahoo Finance

OmniAb to Participate in Two Investor Conferences in September Business Wire

Check out OmniAb's stock price (OABI) in real time CNBC

OmniAb (OABI) Stock: Legitimate Competition To AbCellera In Antibody Discovery Seeking Alpha

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology BioSpace

Why OmniAb, Inc. (OABI) Is One of the Best Biotech Penny Stocks to Invest in Now? Yahoo Finance

OmniAb stock falls after announcing $30 million private placement Investing.com

Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II Business Wire

OmniAb Stock Soars: Is It Time to Buy? StocksToTrade

Latham Represents Ligand in Spin-Off of OmniAb Business Latham & Watkins LLP

OmniAb Q1 2025 slides: Revenue growth and pipeline expansion amid cost controls Investing.com

OmniAb, Inc. (NASDAQ:OABI) Not Lagging Industry On Growth Or Pricing simplywall.st

Matthew Foehr Bought 14% More Shares In OmniAb simplywall.st

The OmniAb® Platform: Human Sequence Antibodies from Mouse, Rat and Chicken Genetic Engineering and Biotechnology News

GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement PR Newswire

Will OmniAb Inc. Equity Warrant stock outperform value stocks - Quarterly Risk Review & Weekly High Return Forecasts Trung tâm Dự báo KTTV quốc gia

Ligand Distribution of OmniAb Complete and Business Combination Closed Business Wire

Advertorial: OmniAb Genetic Engineering and Biotechnology News

Can OmniAb Inc. stock rebound after recent weakness - Market Trend Summary & Technical Buy Zone Confirmation Trung tâm Dự báo KTTV quốc gia

Advertorial: OmniAb Genetic Engineering and Biotechnology News

Ligand out-licenses OmniAb platform to Gilead The Pharma Letter

Comparing Astellas Pharma (OTCMKTS:ALPMY) and OmniAb (NASDAQ:OABI) Defense World

OmniAb (NASDAQ:OABI) Receives Sell (E+) Rating from Weiss Ratings Defense World